Alexion

Alexion, founded in 1992, is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines for individuals affected by severe and life-threatening rare disorders. With a strong focus on addressing unmet medical needs, Alexion leverages its expertise in complement biology and other scientific platforms to develop transformative therapies. The company's commitment extends to delivering these critical treatments to patients worldwide, aiming to make a profound difference in their lives and the lives of their families. Its product portfolio is centered on novel molecules designed to target specific disease pathways, reflecting a deep investment in scientific research and development within the biotechnology and pharmaceutical sectors.

Operating with a significant global footprint, Alexion employs between 5,000 and 10,000 individuals. This dedicated workforce drives the company's mission forward, contributing to its extensive research, manufacturing, and patient support initiatives. The company's operational scale and commitment to innovation are key pillars of its strategy. For insights into the individuals driving this mission, one can explore Meet Alexion's team. Alexion's strategic approach involves rigorous scientific inquiry and a patient-centric philosophy, ensuring that its therapeutic advancements are both effective and accessible to those who need them most.

Financially, Alexion reported substantial revenue, underscoring its market position and the demand for its specialized treatments. In its latest reporting period, the company generated $13.6B in revenue, reflecting its significant impact in the rare disease pharmaceutical market. This financial strength supports ongoing research and development efforts, enabling Alexion to pursue new therapeutic avenues and expand its pipeline. TheView more...